Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities

Shock. 2013 Feb;39(2):121-6. doi: 10.1097/SHK.0b013e318280409a.


A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.

Publication types

  • Review

MeSH terms

  • Antifibrinolytic Agents / pharmacology
  • Antifibrinolytic Agents / therapeutic use*
  • Hemorrhage / prevention & control*
  • Humans
  • Postoperative Complications / chemically induced
  • Randomized Controlled Trials as Topic
  • Research
  • Risk Factors
  • Seizures / chemically induced
  • Thrombosis / chemically induced
  • Tranexamic Acid / pharmacology
  • Tranexamic Acid / therapeutic use*
  • Wounds and Injuries / drug therapy*
  • Wounds and Injuries / surgery


  • Antifibrinolytic Agents
  • Tranexamic Acid